210 results on '"Ogale, Sarika"'
Search Results
2. Economic Burden of Recurrence Among Resected Medicare Patients With Early Stage NSCLC
3. Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network
4. Clinical Value of Timely Targeted Therapy for Patients With Advanced Non–Small Cell Lung Cancer With Actionable Driver Oncogenes
5. Comparing first-line (1L) atezolizumab plus bevacizumab (A+B) to lenvatinib (L) or sorafenib (S) in patients with unresectable hepatocellular carcinoma (uHCC): Findings from the National Veteran Health Administration (VHA) database.
6. Atezolizumab plus bevacizumab (A+B) in patients with unresectable hepatocellular carcinoma (uHCC): Real-world experience from a US community oncology network.
7. Racial/ethnic disparities in the effectiveness of atezolizumab plus bevacizumab (A+B) vs. tyrosine kinase inhibitors (TKIs) among veterans with unresectable hepatocellular carcinoma (uHCC).
8. Work disability, lost productivity and associated risk factors in patients diagnosed with systemic lupus erythematosus.
9. Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings
10. Treatment Patterns and Outcomes in Patients with KRAS Wild-Type Metastatic Colorectal Cancer Treated in First Line with Bevacizumab- or Cetuximab-Containing Regimens
11. Cost–effectiveness of Adjuvant Atezolizumab for Patients with Stage II–IIIA PD-L1+ Non-Small-Cell Lung Cancer
12. Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database
13. Real-world adjuvant chemotherapy patterns and outcomes among elderly patients with resected early non-small-cell lung cancer in the USA
14. Economic Evaluation of Tocilizumab Monotherapy Compared to Adalimumab Monotherapy in the Treatment of Severe Active Rheumatoid Arthritis
15. Estimating recurrences prevented and costs avoided with atezolizumab in early non‐small cell lung cancer in the United States
16. 797 Real-world treatment duration of atezolizumab+carboplatin+etoposide among older patients with extensive-stage small cell lung cancer (ES-SCLC) and the impact of performance status and brain metastases
17. Use of Anti-Tumor Necrosis Factor Therapy: A Retrospective Study of Monotherapy and Adherence to Combination Therapy with Non-Biologic Disease-Modifying Anti-Rheumatic Drugs
18. Associations Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC
19. Estimating recurrences prevented and costs avoided with atezolizumab in early non‐small cell lung cancer in the United States.
20. Assessing Methotrexate Adherence in Rheumatoid Arthritis: A Cross-Sectional Survey
21. Comparison of Biologic Disease-Modifying Antirheumatic Drug Therapy Persistence Between Biologics Among Rheumatoid Arthritis Patients Switching from Another Biologic
22. Comparison of Healthcare Costs Between Rheumatoid Arthritis Patients Treated with Infused Biologics After Switching from Another Biologic
23. Real-world adherence and persistence with anaplastic lymphoma kinase inhibitors in non–small cell lung cancer
24. Response to Biologic Disease-Modifying Anti-Rheumatic Drugs after Discontinuation of Anti-Tumor Necrosis Factor Alpha Agents for Rheumatoid Arthritis
25. Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy
26. Association Between Medicare's National Coverage Determination and Utilization of Next-Generation Sequencing
27. Cardiovascular Events Associated With Ipratropium Bromide in COPD
28. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: Results from an analysis of data from a US claims database
29. Real-world evidence of cancer immunotherapy (CIT) combination treatment in first-line (1L) extensive-stage small cell lung cancer (ES-SCLC).
30. Real-world patterns of biomarker testing and targeted therapy in metastatic non-small cell lung cancer (mNSCLC) in the community oncology setting.
31. Cost-effectiveness of atezolizumab monotherapy versus pembrolizumab monotherapy for first-line (1L) treatment of metastatic non-small cell lung cancer (mNSCLC).
32. Oral involvement in primary Sjogren syndrome
33. A RESPONSE TO “THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER”
34. Increased Bacillus Calmette-Guérin Treatment Intensity Associated With Improved Outcomes in Elderly Patients With Non–Muscle-invasive Bladder Cancer in United States Clinical Practice
35. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study
36. Validity of Cost and Utility Results?
37. The association between Medicaid insurance, biomarker testing, and outcomes in patients with advanced non-small cell lung cancer (aNSCLC).
38. The association between Medicare’s next generation sequencing (NGS), national coverage decision (NCD), and NGS utilization.
39. Cost of cystectomy-related complications in patients with bladder cancer in the United States
40. HSR20-084: Real-World Adherence and Persistence of ALK Inhibitors in Non-Small Cell Lung Cancer (NSCLC)
41. Real-world evidence of the impact of prior antibiotic exposure on immune checkpoint inhibitor outcomes in patients with metastatic urothelial cancer.
42. Cisplatin Ineligibility for Patients With Metastatic Urothelial Carcinoma: A Survey of Clinical Practice Perspectives Among US Oncologists
43. Response
44. Additional file 1: of Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database
45. THE RISK OF CARDIOVASCULAR EVENTS ASSOCIATED WITH INHALED LONG-ACTING BETA-2-ADRENORECEPTOR AGONISTS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
46. PP01.107 Patient Characteristics and Treatment Patterns in Biomarker Selected Early Non-Small Cell Lung Cancer
47. PP01.97 Real-World Treatment Patterns Among Resected Patients With Non-Small Cell Lung Cancer Receiving Adjuvant Atezolizumab
48. PD18-09 INCREASED BACILLUS CALMETTE-GUÉRIN TREATMENT INTENSITY ASSOCIATED WITH IMPROVED OUTCOMES IN ELDERLY PATIENTS WITH NON–MUSCLE-INVASIVE BLADDER CANCER
49. Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's Lymphoma
50. Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.